Advertisement

Physician's First Watch Archive

Medical news from NEJM Journal Watch

July 28, 2014

By Amy Orciari Herman

Edited by Susan Sadoughi, MD

Hepatitis E virus (HEV) infection is more prevalent in England than previously believed, a Lancet study finds.

Some 225,000 blood donations collected in southeastern England in 2012-2013 were screened retrospectively for HEV …

By Amy Orciari Herman

Edited by Susan Sadoughi, MD

The percentage of U.S. teens who reported ever using synthetic human growth hormone without a prescription more than doubled from 2012 to 2013 — from 5% to 11% — according …

By Amy Orciari Herman

Edited by Susan Sadoughi, MD

Two new, all-oral drug regimens are largely effective and well tolerated in patients with chronic hepatitis C (HCV) infection, according to two industry-funded studies in the Lancet. A Lancet commentator, while enthusiastic about the drugs' efficacy, says their high cost will keep them out of the hands …

July 25, 2014

By Kelly Young

Edited by William E. Chavey, MD, MS

Prenatal dalteparin does not reduce the incidence of pregnancy loss, placenta-mediated pregnancy complications, or venous thromboembolism among high-risk women with thrombophilia, according to an open-label trial …

By Amy Orciari Herman

Edited by William E. Chavey, MD, MS

Rates of vaccination against human papillomavirus increased modestly among adolescents from 2012 to 2013, but missed opportunities for vaccination persisted, according to an MMWR article.

Analyzing data from …

By Kristin J. Kelley

The FDA has approved a new abuse-deterrent treatment for severe pain — oxycodone hydrochloride and naloxone hydrochloride extended-release tablets marketed as Targiniq ER.

Approval was based on data from a clinical trial of …

By Amy Orciari Herman

Edited by William E. Chavey, MD, MS

Patients with diabetes might face nearly a 50% increased risk for head and neck cancers, according to a retrospective, case-control study in JAMA Otolaryngology—Head & …

July 24, 2014

By Joe Elia

Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM

Despite being widely recommended as a first-line intervention in low-back pain, acetaminophen does no better than placebo, according to a Lancet study.

Some 1650 …

Pages

Advertisement
Advertisement
Advertisement